SAN DIEGO, Aug. 17 /PRNewswire/ -- Immusol announced today that Gerard A. Wills has joined the Company as its Chief Financial Officer.
Mr. Wills recently served as the Vice President, Chief Financial Officer and Treasurer of Nanogen, Inc., a developer of molecular and point-of-care diagnostic products. Prior to that Mr. Wills was the Chief Financial Officer, Vice President, Finance with Trega Biosciences, Inc. from 1999 until its acquisition by Lion Bioscience of Heidelberg, Germany in March 2001. From 1993 to 1999, Mr. Wills was the Chief Financial Officer, Vice President, Finance with Molecular Biosystems, Inc. and from 1990 to 1993 he was Corporate Manager of Finance with Maxwell Laboratories, Inc. Prior to 1990, Mr. Wills held a number of corporate controller and accounting positions with Intermark, Inc., Allied Signal and Ernst & Ernst.
"I am very pleased to welcome Jerry to the Immusol team," commented Dr. Tsvi Goldenberg, Immusol Chairman and CEO. "We look forward to his contributions as Jerry brings over 25 years of experience in financial and accounting matters and specific expertise as a Chief Financial Officer at three public biotech companies where he was instrumental in developing and operating the financial, accounting and investor relations departments."
Mr. Wills received a Bachelor of Business Administration degree with a concentration in Accountancy from the University of Notre Dame.
Immusol is a privately-held San Diego-based biopharmaceutical company engaged in the discovery and development of novel therapies to treat human diseases. Immusol uses an integrated approach, starting with a proprietary discovery technology, to identify therapeutic molecules involved in the areas of cancer, viral infection, ophthalmology, and metabolic diseases. Based on these discoveries, Immusol develops small molecule and protein-based therapies alone or in collaboration with drug development partners. Immusol's lead drug candidate, ChelASE, is being studied in clinical trials for the treatment of keloids and hypertrophic scars. Other drug candidates are in various stages of pre-clinical and clinical development.